| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urologic Neoplasms | 62 | 2019 | 320 | 17.190 |
Why?
|
| Carcinoma, Transitional Cell | 87 | 2021 | 811 | 15.340 |
Why?
|
| Urinary Bladder Neoplasms | 133 | 2020 | 2267 | 14.670 |
Why?
|
| Urothelium | 36 | 2021 | 277 | 7.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 121 | 2021 | 11626 | 5.980 |
Why?
|
| Kidney Neoplasms | 70 | 2018 | 4280 | 5.580 |
Why?
|
| Carcinoma, Renal Cell | 65 | 2018 | 3164 | 5.570 |
Why?
|
| Antineoplastic Agents | 99 | 2021 | 13678 | 4.430 |
Why?
|
| Cisplatin | 46 | 2021 | 1664 | 4.080 |
Why?
|
| Vinblastine | 25 | 2019 | 503 | 3.650 |
Why?
|
| Taxoids | 29 | 2019 | 671 | 3.500 |
Why?
|
| Cystectomy | 32 | 2019 | 693 | 3.450 |
Why?
|
| Salvage Therapy | 16 | 2018 | 1279 | 2.710 |
Why?
|
| Deoxycytidine | 25 | 2019 | 839 | 2.420 |
Why?
|
| Molecular Targeted Therapy | 19 | 2019 | 2755 | 2.390 |
Why?
|
| Carcinoma | 20 | 2018 | 2385 | 2.300 |
Why?
|
| Benzenesulfonates | 12 | 2010 | 169 | 2.250 |
Why?
|
| Pyrroles | 17 | 2014 | 1145 | 2.190 |
Why?
|
| Antibodies, Monoclonal | 29 | 2021 | 9300 | 2.160 |
Why?
|
| Neoplasm Metastasis | 48 | 2019 | 4881 | 2.050 |
Why?
|
| Disease-Free Survival | 59 | 2021 | 6920 | 1.950 |
Why?
|
| Indoles | 17 | 2014 | 1839 | 1.930 |
Why?
|
| Immunotherapy | 20 | 2021 | 4526 | 1.910 |
Why?
|
| Nomograms | 6 | 2018 | 230 | 1.910 |
Why?
|
| Prostatic Neoplasms | 44 | 2019 | 11211 | 1.870 |
Why?
|
| Angiogenesis Inhibitors | 17 | 2017 | 2039 | 1.650 |
Why?
|
| Ureteral Neoplasms | 5 | 2016 | 110 | 1.580 |
Why?
|
| Survival Analysis | 55 | 2019 | 10252 | 1.570 |
Why?
|
| Pyridines | 15 | 2019 | 2841 | 1.550 |
Why?
|
| Paclitaxel | 15 | 2019 | 1708 | 1.520 |
Why?
|
| Organoplatinum Compounds | 7 | 2017 | 408 | 1.500 |
Why?
|
| Chemotherapy, Adjuvant | 28 | 2018 | 3493 | 1.430 |
Why?
|
| Urogenital Neoplasms | 4 | 2015 | 138 | 1.330 |
Why?
|
| Protein Kinase Inhibitors | 18 | 2016 | 5584 | 1.310 |
Why?
|
| Neoadjuvant Therapy | 22 | 2019 | 2775 | 1.210 |
Why?
|
| Endonucleases | 4 | 2017 | 379 | 1.180 |
Why?
|
| Prognosis | 62 | 2019 | 29264 | 1.180 |
Why?
|
| Neoplasm Invasiveness | 27 | 2021 | 3627 | 1.170 |
Why?
|
| Humans | 397 | 2021 | 752741 | 1.160 |
Why?
|
| Carboplatin | 17 | 2019 | 802 | 1.160 |
Why?
|
| Niacinamide | 16 | 2014 | 417 | 1.110 |
Why?
|
| Phenylthiohydantoin | 6 | 2016 | 196 | 1.100 |
Why?
|
| Platinum | 7 | 2018 | 232 | 1.080 |
Why?
|
| Imidazoles | 7 | 2019 | 1201 | 1.080 |
Why?
|
| Treatment Outcome | 113 | 2018 | 64017 | 1.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 14 | 2018 | 630 | 1.050 |
Why?
|
| Neoplasm Staging | 40 | 2018 | 11091 | 1.030 |
Why?
|
| Phenylurea Compounds | 16 | 2014 | 527 | 1.030 |
Why?
|
| Bone Neoplasms | 13 | 2018 | 2546 | 0.970 |
Why?
|
| Male | 235 | 2021 | 354311 | 0.960 |
Why?
|
| Muscles | 5 | 2021 | 1618 | 0.940 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2016 | 1517 | 0.930 |
Why?
|
| Aged | 167 | 2021 | 165629 | 0.920 |
Why?
|
| Orchiectomy | 9 | 2015 | 473 | 0.910 |
Why?
|
| TOR Serine-Threonine Kinases | 9 | 2016 | 2101 | 0.870 |
Why?
|
| Prostate-Specific Antigen | 18 | 2019 | 2517 | 0.860 |
Why?
|
| Androgen Receptor Antagonists | 5 | 2016 | 117 | 0.860 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2020 | 9305 | 0.810 |
Why?
|
| Androgen Antagonists | 15 | 2018 | 1390 | 0.810 |
Why?
|
| Vascular Endothelial Growth Factor A | 12 | 2018 | 3512 | 0.800 |
Why?
|
| Sirolimus | 9 | 2014 | 1568 | 0.780 |
Why?
|
| Survival Rate | 31 | 2019 | 12802 | 0.780 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2019 | 8460 | 0.780 |
Why?
|
| Adenocarcinoma | 15 | 2018 | 6387 | 0.770 |
Why?
|
| Middle Aged | 163 | 2021 | 216054 | 0.770 |
Why?
|
| Prostatectomy | 10 | 2017 | 1908 | 0.770 |
Why?
|
| Platinum Compounds | 6 | 2018 | 97 | 0.760 |
Why?
|
| Drug Administration Schedule | 25 | 2018 | 4943 | 0.750 |
Why?
|
| Kaplan-Meier Estimate | 28 | 2018 | 6542 | 0.750 |
Why?
|
| Watchful Waiting | 5 | 2018 | 499 | 0.740 |
Why?
|
| Aged, 80 and over | 76 | 2019 | 58361 | 0.720 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2013 | 621 | 0.710 |
Why?
|
| Pyrimidines | 6 | 2019 | 2987 | 0.710 |
Why?
|
| Indazoles | 4 | 2018 | 291 | 0.700 |
Why?
|
| Muscle Neoplasms | 4 | 2018 | 138 | 0.690 |
Why?
|
| Clinical Trials, Phase III as Topic | 15 | 2015 | 850 | 0.660 |
Why?
|
| Female | 170 | 2021 | 385090 | 0.650 |
Why?
|
| Benzoxazoles | 1 | 2019 | 78 | 0.640 |
Why?
|
| Combined Modality Therapy | 22 | 2019 | 8660 | 0.630 |
Why?
|
| Urology | 4 | 2017 | 409 | 0.600 |
Why?
|
| Fluorouracil | 8 | 2014 | 1633 | 0.600 |
Why?
|
| Cancer Vaccines | 4 | 2014 | 1041 | 0.590 |
Why?
|
| Radium | 3 | 2018 | 72 | 0.590 |
Why?
|
| DNA Copy Number Variations | 6 | 2018 | 2009 | 0.570 |
Why?
|
| Radiotherapy | 7 | 2017 | 1533 | 0.570 |
Why?
|
| Morpholines | 2 | 2019 | 572 | 0.560 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 68 | 0.550 |
Why?
|
| Societies, Medical | 8 | 2019 | 3802 | 0.540 |
Why?
|
| Methotrexate | 18 | 2015 | 1729 | 0.520 |
Why?
|
| Gene Dosage | 3 | 2020 | 1255 | 0.520 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 100 | 0.520 |
Why?
|
| Clinical Trials as Topic | 24 | 2018 | 7970 | 0.520 |
Why?
|
| Health Planning Guidelines | 3 | 2014 | 162 | 0.520 |
Why?
|
| BCG Vaccine | 4 | 2018 | 371 | 0.520 |
Why?
|
| Perioperative Care | 4 | 2015 | 1016 | 0.520 |
Why?
|
| Neovascularization, Pathologic | 7 | 2016 | 2654 | 0.520 |
Why?
|
| Radiopharmaceuticals | 4 | 2014 | 2675 | 0.520 |
Why?
|
| Prednisone | 7 | 2017 | 1585 | 0.510 |
Why?
|
| Follow-Up Studies | 32 | 2020 | 39223 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2019 | 10057 | 0.490 |
Why?
|
| Disease Progression | 25 | 2018 | 13364 | 0.490 |
Why?
|
| Infusions, Intravenous | 9 | 2017 | 2289 | 0.490 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2017 | 5199 | 0.490 |
Why?
|
| Mutation | 20 | 2020 | 29981 | 0.490 |
Why?
|
| DNA-Binding Proteins | 6 | 2019 | 9664 | 0.490 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 3 | 2020 | 105 | 0.480 |
Why?
|
| Anilides | 3 | 2015 | 409 | 0.460 |
Why?
|
| Carcinoma in Situ | 3 | 2017 | 805 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 10914 | 0.440 |
Why?
|
| Kallikreins | 3 | 2016 | 258 | 0.440 |
Why?
|
| Spain | 9 | 2015 | 467 | 0.430 |
Why?
|
| Alpha Particles | 1 | 2012 | 29 | 0.430 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2017 | 1074 | 0.430 |
Why?
|
| Adult | 94 | 2021 | 216658 | 0.420 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2016 | 1666 | 0.420 |
Why?
|
| Lymph Node Excision | 8 | 2017 | 1281 | 0.420 |
Why?
|
| Patient-Centered Care | 3 | 2012 | 1445 | 0.420 |
Why?
|
| Interferon-alpha | 9 | 2013 | 909 | 0.420 |
Why?
|
| Gene Expression Profiling | 8 | 2018 | 9431 | 0.420 |
Why?
|
| Serum Albumin | 1 | 2015 | 680 | 0.410 |
Why?
|
| Sulfonamides | 3 | 2018 | 1963 | 0.400 |
Why?
|
| Drugs, Investigational | 2 | 2011 | 214 | 0.400 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2018 | 1207 | 0.400 |
Why?
|
| Fluorine Radioisotopes | 1 | 2014 | 445 | 0.390 |
Why?
|
| Receptor, erbB-2 | 4 | 2016 | 2474 | 0.390 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2018 | 3605 | 0.390 |
Why?
|
| Ifosfamide | 3 | 1998 | 236 | 0.380 |
Why?
|
| Designer Drugs | 1 | 2010 | 20 | 0.380 |
Why?
|
| Hyponatremia | 1 | 2013 | 286 | 0.380 |
Why?
|
| Muscle, Smooth | 5 | 2017 | 943 | 0.370 |
Why?
|
| Maximum Tolerated Dose | 5 | 2017 | 887 | 0.360 |
Why?
|
| Benzamides | 7 | 2018 | 1382 | 0.360 |
Why?
|
| Europe | 12 | 2017 | 3359 | 0.360 |
Why?
|
| Proportional Hazards Models | 18 | 2017 | 12423 | 0.360 |
Why?
|
| Urinary Bladder | 6 | 2018 | 1181 | 0.360 |
Why?
|
| Doxorubicin | 11 | 2015 | 2242 | 0.360 |
Why?
|
| Genomics | 6 | 2018 | 5743 | 0.350 |
Why?
|
| Quality of Life | 12 | 2018 | 13044 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 11 | 2018 | 7355 | 0.350 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2014 | 647 | 0.340 |
Why?
|
| Rectum | 1 | 2014 | 907 | 0.340 |
Why?
|
| Lymphatic Metastasis | 11 | 2017 | 2936 | 0.340 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 577 | 0.340 |
Why?
|
| Immunotherapy, Active | 1 | 2009 | 61 | 0.330 |
Why?
|
| Hemoglobins | 2 | 2017 | 1537 | 0.330 |
Why?
|
| Liver Neoplasms | 10 | 2017 | 4311 | 0.320 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 2033 | 0.320 |
Why?
|
| Nitriles | 8 | 2016 | 960 | 0.320 |
Why?
|
| Drug Carriers | 1 | 2013 | 709 | 0.320 |
Why?
|
| Sodium | 1 | 2013 | 1625 | 0.310 |
Why?
|
| Methionine | 1 | 2010 | 591 | 0.310 |
Why?
|
| Stomach Neoplasms | 4 | 2012 | 1356 | 0.310 |
Why?
|
| Retrospective Studies | 38 | 2019 | 78758 | 0.310 |
Why?
|
| Interleukin-8 | 1 | 2011 | 695 | 0.310 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2018 | 67 | 0.310 |
Why?
|
| Neutropenia | 5 | 2017 | 893 | 0.310 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 111 | 0.300 |
Why?
|
| Tetrahydroisoquinolines | 3 | 2014 | 90 | 0.300 |
Why?
|
| Predictive Value of Tests | 13 | 2018 | 15164 | 0.300 |
Why?
|
| Sarcoma | 4 | 2011 | 1903 | 0.300 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2013 | 664 | 0.290 |
Why?
|
| Thromboembolism | 2 | 2012 | 996 | 0.290 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 6364 | 0.290 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2010 | 1370 | 0.290 |
Why?
|
| Administration, Oral | 9 | 2019 | 3941 | 0.290 |
Why?
|
| Palliative Care | 5 | 2012 | 3546 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2492 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 708 | 0.280 |
Why?
|
| Colon | 1 | 2014 | 1800 | 0.270 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2018 | 104 | 0.270 |
Why?
|
| Drug Delivery Systems | 2 | 2016 | 2229 | 0.270 |
Why?
|
| Prospective Studies | 21 | 2018 | 53863 | 0.270 |
Why?
|
| MicroRNAs | 4 | 2017 | 3767 | 0.270 |
Why?
|
| Patient Selection | 9 | 2019 | 4232 | 0.260 |
Why?
|
| Nephrectomy | 8 | 2017 | 1046 | 0.260 |
Why?
|
| Medical Oncology | 4 | 2018 | 2298 | 0.260 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 801 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 2927 | 0.260 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2009 | 642 | 0.260 |
Why?
|
| Biological Products | 1 | 2014 | 881 | 0.260 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 3700 | 0.250 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2005 | 89 | 0.250 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2011 | 621 | 0.250 |
Why?
|
| Colorectal Neoplasms | 7 | 2016 | 6855 | 0.240 |
Why?
|
| Nails | 3 | 1991 | 293 | 0.240 |
Why?
|
| Time Factors | 27 | 2018 | 40195 | 0.230 |
Why?
|
| Lung Neoplasms | 14 | 2015 | 13263 | 0.230 |
Why?
|
| DNA Repair | 3 | 2018 | 2058 | 0.220 |
Why?
|
| Protective Agents | 2 | 2014 | 156 | 0.220 |
Why?
|
| Administration, Intravesical | 3 | 2018 | 90 | 0.220 |
Why?
|
| Double-Blind Method | 11 | 2017 | 12202 | 0.220 |
Why?
|
| Treatment Failure | 5 | 2013 | 2642 | 0.220 |
Why?
|
| Molecular Chaperones | 3 | 2018 | 738 | 0.220 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 1371 | 0.220 |
Why?
|
| Risk Assessment | 14 | 2018 | 23554 | 0.210 |
Why?
|
| Signal Transduction | 8 | 2016 | 23512 | 0.210 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 491 | 0.210 |
Why?
|
| Thalidomide | 3 | 2017 | 874 | 0.210 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 1210 | 0.200 |
Why?
|
| Tegafur | 3 | 1998 | 49 | 0.200 |
Why?
|
| Bone Remodeling | 3 | 2018 | 578 | 0.200 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 3572 | 0.200 |
Why?
|
| Drug Synergism | 3 | 2019 | 1768 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 4121 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 1044 | 0.200 |
Why?
|
| Leucovorin | 4 | 1998 | 637 | 0.200 |
Why?
|
| Nanoparticles | 1 | 2013 | 1944 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 2945 | 0.200 |
Why?
|
| Italy | 2 | 2013 | 831 | 0.190 |
Why?
|
| Risk Factors | 22 | 2018 | 73094 | 0.190 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 16789 | 0.190 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 2553 | 0.190 |
Why?
|
| Urinary Diversion | 2 | 2018 | 138 | 0.190 |
Why?
|
| Dioxoles | 2 | 2011 | 103 | 0.190 |
Why?
|
| RNA, Messenger | 7 | 2016 | 13011 | 0.190 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2015 | 2606 | 0.190 |
Why?
|
| Brachytherapy | 3 | 2017 | 1247 | 0.190 |
Why?
|
| Vinca Alkaloids | 2 | 2011 | 35 | 0.190 |
Why?
|
| Cholangiocarcinoma | 1 | 2006 | 534 | 0.180 |
Why?
|
| Bleomycin | 3 | 1991 | 513 | 0.180 |
Why?
|
| Alkaline Phosphatase | 2 | 2013 | 866 | 0.180 |
Why?
|
| Drug Therapy | 2 | 2014 | 501 | 0.180 |
Why?
|
| Cohort Studies | 16 | 2018 | 40939 | 0.180 |
Why?
|
| Breast Neoplasms | 16 | 2011 | 20914 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2014 | 4062 | 0.180 |
Why?
|
| Lymph Nodes | 5 | 2017 | 3503 | 0.180 |
Why?
|
| Cyclin E | 1 | 2020 | 172 | 0.180 |
Why?
|
| Patient Care Team | 2 | 2008 | 2555 | 0.170 |
Why?
|
| Animals | 19 | 2019 | 169600 | 0.170 |
Why?
|
| Hemangioendothelioma | 2 | 1990 | 122 | 0.170 |
Why?
|
| Genetic Variation | 1 | 2014 | 6567 | 0.160 |
Why?
|
| Breast Neoplasms, Male | 2 | 1998 | 214 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2005 | 1119 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2019 | 171 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7941 | 0.160 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 151 | 0.160 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2016 | 42 | 0.160 |
Why?
|
| Bronchial Neoplasms | 2 | 1996 | 112 | 0.160 |
Why?
|
| Venous Thromboembolism | 3 | 2016 | 1770 | 0.160 |
Why?
|
| Diphosphonates | 2 | 2013 | 628 | 0.160 |
Why?
|
| Androstenes | 3 | 2014 | 170 | 0.160 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 131 | 0.160 |
Why?
|
| Radioisotopes | 3 | 2018 | 503 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2012 | 1775 | 0.160 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1806 | 0.150 |
Why?
|
| Asthenia | 1 | 2017 | 16 | 0.150 |
Why?
|
| Disease Management | 4 | 2017 | 2473 | 0.150 |
Why?
|
| Antidotes | 1 | 1998 | 140 | 0.150 |
Why?
|
| Congresses as Topic | 2 | 2012 | 767 | 0.150 |
Why?
|
| Heat-Shock Proteins | 2 | 2018 | 808 | 0.140 |
Why?
|
| Gene Deletion | 2 | 2015 | 2746 | 0.140 |
Why?
|
| Cryosurgery | 3 | 2016 | 458 | 0.140 |
Why?
|
| Cyclin D1 | 1 | 1998 | 462 | 0.140 |
Why?
|
| Galectins | 1 | 2019 | 282 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 5337 | 0.140 |
Why?
|
| Random Allocation | 2 | 2018 | 2426 | 0.140 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 323 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2020 | 747 | 0.140 |
Why?
|
| Neoplasms | 11 | 2018 | 21976 | 0.140 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 801 | 0.130 |
Why?
|
| Rosa | 1 | 2015 | 8 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 423 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 2 | 2013 | 118 | 0.130 |
Why?
|
| E2F3 Transcription Factor | 1 | 2015 | 40 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2018 | 599 | 0.130 |
Why?
|
| Androstenols | 2 | 2013 | 25 | 0.130 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 189 | 0.130 |
Why?
|
| BRCA1 Protein | 2 | 2015 | 1158 | 0.130 |
Why?
|
| Histone Code | 1 | 2016 | 161 | 0.130 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11395 | 0.130 |
Why?
|
| Kidney Pelvis | 1 | 2016 | 188 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2017 | 452 | 0.130 |
Why?
|
| Adenoma, Villous | 1 | 2014 | 15 | 0.120 |
Why?
|
| Internationality | 2 | 2017 | 999 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2018 | 593 | 0.120 |
Why?
|
| Blood Cell Count | 1 | 2015 | 404 | 0.120 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 252 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1996 | 599 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 161 | 0.120 |
Why?
|
| Cluster Analysis | 3 | 2017 | 2719 | 0.120 |
Why?
|
| Retreatment | 1 | 2015 | 608 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 12250 | 0.120 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1994 | 84 | 0.110 |
Why?
|
| Androstadienes | 2 | 2013 | 344 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1593 | 0.110 |
Why?
|
| Recombinant Proteins | 7 | 2014 | 6624 | 0.110 |
Why?
|
| Cystoscopy | 2 | 2012 | 133 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2017 | 545 | 0.110 |
Why?
|
| Geriatrics | 1 | 2018 | 398 | 0.110 |
Why?
|
| Remission Induction | 5 | 2010 | 2386 | 0.110 |
Why?
|
| Standard of Care | 1 | 2017 | 566 | 0.110 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2014 | 88 | 0.110 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2559 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2018 | 1060 | 0.110 |
Why?
|
| Estrogen Antagonists | 2 | 2008 | 153 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1084 | 0.110 |
Why?
|
| Wilms Tumor | 2 | 1994 | 375 | 0.110 |
Why?
|
| Achievement | 1 | 2014 | 290 | 0.110 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 1992 | 171 | 0.110 |
Why?
|
| Cyclophosphamide | 7 | 2000 | 2252 | 0.110 |
Why?
|
| Biopsy | 6 | 2017 | 6771 | 0.110 |
Why?
|
| Incidence | 6 | 2016 | 21146 | 0.110 |
Why?
|
| Capillaries | 3 | 1991 | 775 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 3 | 2008 | 419 | 0.110 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2014 | 162 | 0.110 |
Why?
|
| Constipation | 1 | 2017 | 547 | 0.100 |
Why?
|
| Leiomyoma | 1 | 1997 | 720 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 1993 | 773 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 3304 | 0.100 |
Why?
|
| HIV Seropositivity | 2 | 1995 | 967 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 2846 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1798 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1073 | 0.100 |
Why?
|
| Seminoma | 1 | 2012 | 139 | 0.100 |
Why?
|
| Urinary Tract | 1 | 2014 | 313 | 0.100 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2011 | 98 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2016 | 782 | 0.090 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 809 | 0.090 |
Why?
|
| Expert Testimony | 1 | 2013 | 359 | 0.090 |
Why?
|
| Raynaud Disease | 1 | 1991 | 78 | 0.090 |
Why?
|
| Gene Frequency | 2 | 2015 | 3591 | 0.090 |
Why?
|
| Microscopy | 3 | 1991 | 903 | 0.090 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 44 | 0.090 |
Why?
|
| Albumins | 1 | 2013 | 564 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 2 | 2017 | 693 | 0.090 |
Why?
|
| DNA Damage | 2 | 2018 | 2442 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2015 | 1099 | 0.090 |
Why?
|
| Geriatric Assessment | 3 | 2018 | 1390 | 0.090 |
Why?
|
| Drug Approval | 1 | 2017 | 786 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 378 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2013 | 1917 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 2 | 2012 | 421 | 0.090 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 726 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2012 | 3530 | 0.090 |
Why?
|
| Cell Survival | 2 | 2019 | 5860 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 4806 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 8947 | 0.090 |
Why?
|
| Mitoxantrone | 1 | 1990 | 152 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2018 | 2617 | 0.090 |
Why?
|
| Fatigue | 1 | 2017 | 1536 | 0.090 |
Why?
|
| Consensus | 3 | 2019 | 3023 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2014 | 542 | 0.090 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 333 | 0.090 |
Why?
|
| Logistic Models | 6 | 2018 | 13441 | 0.090 |
Why?
|
| Half-Life | 1 | 2010 | 663 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 939 | 0.090 |
Why?
|
| Propensity Score | 4 | 2018 | 1828 | 0.090 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1343 | 0.090 |
Why?
|
| Linear Models | 2 | 2010 | 5965 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 1611 | 0.080 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2012 | 341 | 0.080 |
Why?
|
| Evidence-Based Medicine | 8 | 2014 | 3652 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 568 | 0.080 |
Why?
|
| Observer Variation | 1 | 2015 | 2622 | 0.080 |
Why?
|
| Recurrence | 2 | 2018 | 8422 | 0.080 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 1186 | 0.080 |
Why?
|
| Codon | 1 | 2010 | 612 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 1997 | 1505 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2010 | 2450 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 3021 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2335 | 0.080 |
Why?
|
| Databases, Factual | 6 | 2018 | 7805 | 0.080 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 3766 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 976 | 0.070 |
Why?
|
| Progestins | 1 | 2009 | 309 | 0.070 |
Why?
|
| Paresthesia | 1 | 1988 | 161 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2009 | 766 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 3686 | 0.070 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2007 | 33 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2017 | 9863 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 3491 | 0.070 |
Why?
|
| Cell Line | 3 | 2018 | 16004 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 175 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2016 | 4228 | 0.070 |
Why?
|
| Erythema | 1 | 1988 | 261 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2017 | 4315 | 0.070 |
Why?
|
| S Phase | 1 | 2008 | 424 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2014 | 1377 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2008 | 294 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 609 | 0.070 |
Why?
|
| G1 Phase | 1 | 2008 | 414 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2014 | 1402 | 0.070 |
Why?
|
| Tamoxifen | 1 | 1991 | 979 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2009 | 1904 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2014 | 1867 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6493 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2014 | 1060 | 0.070 |
Why?
|
| Postoperative Complications | 3 | 2017 | 15459 | 0.070 |
Why?
|
| Phenotype | 4 | 2016 | 16484 | 0.070 |
Why?
|
| Heart Neoplasms | 1 | 1989 | 368 | 0.070 |
Why?
|
| Mice | 5 | 2019 | 81766 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 497 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2019 | 10508 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2010 | 1522 | 0.060 |
Why?
|
| Growth Substances | 2 | 1998 | 783 | 0.060 |
Why?
|
| Genetic Loci | 1 | 2015 | 2614 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1366 | 0.060 |
Why?
|
| Neutrophils | 1 | 2018 | 3729 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2007 | 262 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2776 | 0.060 |
Why?
|
| Farnesyltranstransferase | 1 | 2005 | 76 | 0.060 |
Why?
|
| Aging | 2 | 2018 | 8752 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1364 | 0.060 |
Why?
|
| Health Status | 1 | 2018 | 4077 | 0.060 |
Why?
|
| Tissue Extracts | 2 | 2016 | 135 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2007 | 475 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 35798 | 0.060 |
Why?
|
| United States | 6 | 2018 | 70772 | 0.060 |
Why?
|
| Risk | 3 | 2013 | 9683 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 4179 | 0.060 |
Why?
|
| Comorbidity | 2 | 2011 | 10450 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 5851 | 0.060 |
Why?
|
| Esophageal Neoplasms | 2 | 2011 | 1606 | 0.060 |
Why?
|
| CpG Islands | 1 | 2008 | 1219 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 652 | 0.060 |
Why?
|
| Diarrhea | 2 | 2009 | 1351 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2008 | 696 | 0.060 |
Why?
|
| Young Adult | 8 | 2018 | 57267 | 0.060 |
Why?
|
| Adolescent | 7 | 2021 | 86713 | 0.060 |
Why?
|
| Naphthalenes | 2 | 2015 | 195 | 0.060 |
Why?
|
| Age Factors | 5 | 2018 | 18460 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 3111 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2010 | 1945 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2940 | 0.060 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 615 | 0.060 |
Why?
|
| Pelvis | 2 | 2017 | 738 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2013 | 3489 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 1152 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3218 | 0.050 |
Why?
|
| Survival | 2 | 2013 | 163 | 0.050 |
Why?
|
| Computational Biology | 1 | 2015 | 3531 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 2927 | 0.050 |
Why?
|
| Quinolones | 2 | 2017 | 369 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2016 | 1604 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2011 | 414 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2011 | 20346 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 3 | 2014 | 778 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 674 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2008 | 825 | 0.050 |
Why?
|
| Tosyl Compounds | 1 | 2002 | 113 | 0.050 |
Why?
|
| Flutamide | 1 | 2002 | 96 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2014 | 2145 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2009 | 1633 | 0.050 |
Why?
|
| Safety | 2 | 2017 | 1179 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 1773 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2010 | 1073 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 1990 | 1160 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2014 | 650 | 0.050 |
Why?
|
| North America | 2 | 2015 | 1255 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2019 | 2987 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2016 | 3349 | 0.050 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 3511 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2012 | 2136 | 0.050 |
Why?
|
| Kinetics | 1 | 2009 | 6482 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2018 | 2893 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2004 | 643 | 0.050 |
Why?
|
| Algorithms | 3 | 2012 | 13984 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2009 | 3220 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 1992 | 647 | 0.050 |
Why?
|
| History, 21st Century | 2 | 2017 | 1552 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 813 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1996 | 378 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8216 | 0.040 |
Why?
|
| DNA | 1 | 2013 | 7312 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2019 | 12165 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2017 | 1127 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2001 | 5144 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 17635 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 3761 | 0.040 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 15433 | 0.040 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2018 | 29 | 0.040 |
Why?
|
| Megestrol Acetate | 1 | 1998 | 18 | 0.040 |
Why?
|
| ras Proteins | 2 | 2016 | 1065 | 0.040 |
Why?
|
| Smoking | 1 | 2015 | 9030 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6352 | 0.040 |
Why?
|
| Models, Biological | 2 | 2014 | 9569 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5338 | 0.040 |
Why?
|
| Orbital Neoplasms | 2 | 1991 | 225 | 0.040 |
Why?
|
| Forecasting | 1 | 2006 | 2956 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1990 | 2259 | 0.040 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 38 | 0.040 |
Why?
|
| International Agencies | 1 | 2017 | 239 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 20026 | 0.040 |
Why?
|
| Quinazolines | 2 | 2014 | 1355 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 183 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 2 | 2011 | 1185 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 1996 | 171 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1994 | 1389 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2002 | 690 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2001 | 1994 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1753 | 0.030 |
Why?
|
| Uracil | 1 | 1997 | 177 | 0.030 |
Why?
|
| Kidney | 1 | 2011 | 7152 | 0.030 |
Why?
|
| Radiography | 3 | 2015 | 7047 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2015 | 6458 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 304 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2016 | 242 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 901 | 0.030 |
Why?
|
| Ureteroscopy | 1 | 2016 | 146 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 5282 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2019 | 706 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 357 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2019 | 1534 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 133 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2014 | 60 | 0.030 |
Why?
|
| Cell Movement | 2 | 2013 | 5222 | 0.030 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2014 | 58 | 0.030 |
Why?
|
| Gene Expression | 3 | 2014 | 7771 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 1998 | 511 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 2042 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1876 | 0.030 |
Why?
|
| Mitomycin | 2 | 1991 | 259 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 780 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 112 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 1994 | 112 | 0.030 |
Why?
|
| Child | 3 | 2017 | 78594 | 0.030 |
Why?
|
| Ureter | 1 | 2016 | 375 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 430 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2016 | 304 | 0.030 |
Why?
|
| Point Mutation | 1 | 1998 | 1619 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 885 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2016 | 622 | 0.030 |
Why?
|
| Procollagen | 1 | 2013 | 186 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2015 | 596 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2693 | 0.030 |
Why?
|
| Choroid Neoplasms | 1 | 1994 | 175 | 0.030 |
Why?
|
| Length of Stay | 2 | 2017 | 6355 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2016 | 549 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2014 | 276 | 0.030 |
Why?
|
| Immunity | 1 | 2018 | 1007 | 0.030 |
Why?
|
| Anemia | 1 | 2002 | 1505 | 0.030 |
Why?
|
| Expert Systems | 1 | 2012 | 80 | 0.030 |
Why?
|
| Triazoles | 1 | 1998 | 909 | 0.030 |
Why?
|
| Publication Bias | 1 | 2013 | 162 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 612 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15657 | 0.030 |
Why?
|
| Polyarteritis Nodosa | 1 | 1992 | 66 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 658 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2011 | 114 | 0.020 |
Why?
|
| Papilloma | 1 | 1992 | 148 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2014 | 673 | 0.020 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1995 | 529 | 0.020 |
Why?
|
| Addison Disease | 1 | 1990 | 49 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 677 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2013 | 543 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 641 | 0.020 |
Why?
|
| Placebos | 1 | 2015 | 1675 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 1992 | 232 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2017 | 1201 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2013 | 592 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1994 | 514 | 0.020 |
Why?
|
| Prostate | 1 | 2018 | 1794 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 965 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 1690 | 0.020 |
Why?
|
| Hypertension | 1 | 2010 | 8614 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1996 | 1279 | 0.020 |
Why?
|
| Tonsillar Neoplasms | 1 | 1990 | 51 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5284 | 0.020 |
Why?
|
| Mitomycins | 1 | 1989 | 47 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1994 | 1276 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2011 | 325 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 1687 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 872 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1997 | 1211 | 0.020 |
Why?
|
| Estrogens | 1 | 2015 | 1573 | 0.020 |
Why?
|
| Apoptosis | 1 | 2005 | 9657 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1184 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1994 | 2633 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1989 | 309 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2019 | 0.020 |
Why?
|
| Quinolines | 1 | 2013 | 746 | 0.020 |
Why?
|
| Interferons | 1 | 1991 | 720 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2018 | 2708 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1997 | 1190 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 1989 | 172 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 1991 | 1526 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2014 | 983 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2766 | 0.020 |
Why?
|
| Patient Preference | 1 | 2014 | 899 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1997 | 2087 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5149 | 0.020 |
Why?
|
| Magnesium | 1 | 1990 | 813 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 6169 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1795 | 0.020 |
Why?
|
| Heart Failure | 1 | 2011 | 11096 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 563 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 1543 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2945 | 0.020 |
Why?
|
| Thiazoles | 1 | 2013 | 1484 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 1417 | 0.020 |
Why?
|
| Acromegaly | 1 | 1989 | 348 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1995 | 2129 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1630 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1990 | 550 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 1992 | 969 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1990 | 603 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 500 | 0.020 |
Why?
|
| Spinal Neoplasms | 1 | 1992 | 706 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1994 | 898 | 0.020 |
Why?
|
| Methylation | 1 | 2008 | 1112 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 676 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1990 | 742 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 2584 | 0.020 |
Why?
|
| Lymphoma | 1 | 1994 | 1892 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 611 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 4248 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2015 | 3469 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 2816 | 0.020 |
Why?
|
| Hepatitis A virus | 1 | 2004 | 15 | 0.020 |
Why?
|
| Foot | 1 | 1988 | 542 | 0.020 |
Why?
|
| Cell Division | 2 | 2004 | 4549 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 1721 | 0.010 |
Why?
|
| Transgenes | 1 | 2008 | 1012 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5974 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 948 | 0.010 |
Why?
|
| ROC Curve | 1 | 2011 | 3558 | 0.010 |
Why?
|
| Androgens | 1 | 2011 | 1289 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2017 | 3161 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 15657 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2015 | 2083 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2018 | 14596 | 0.010 |
Why?
|
| Hand | 1 | 1988 | 894 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1988 | 587 | 0.010 |
Why?
|
| Menopause | 1 | 1991 | 1641 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2004 | 395 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 1270 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2013 | 2597 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 1723 | 0.010 |
Why?
|
| Syndrome | 1 | 1988 | 3261 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 767 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5124 | 0.010 |
Why?
|
| Estradiol | 1 | 2008 | 2025 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1993 | 5006 | 0.010 |
Why?
|
| Vaccination | 1 | 2011 | 3354 | 0.010 |
Why?
|
| Binding Sites | 1 | 2008 | 6118 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1992 | 2302 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 21904 | 0.010 |
Why?
|
| Rats | 1 | 1994 | 24248 | 0.010 |
Why?
|
| Research Design | 1 | 2014 | 6118 | 0.010 |
Why?
|
| Vincristine | 2 | 1991 | 1050 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 4562 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2006 | 2058 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 4723 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 9408 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8971 | 0.010 |
Why?
|
| Platelet Count | 1 | 1997 | 784 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8413 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 695 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12769 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3871 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 379 | 0.010 |
Why?
|
| Stomatitis | 1 | 1995 | 271 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1995 | 435 | 0.010 |
Why?
|
| Procarbazine | 1 | 1991 | 181 | 0.010 |
Why?
|
| Lomustine | 1 | 1991 | 59 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6233 | 0.010 |
Why?
|
| Tuberculosis, Endocrine | 1 | 1990 | 1 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 1993 | 292 | 0.010 |
Why?
|
| Sputum | 1 | 1993 | 480 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1676 | 0.010 |
Why?
|
| Etoposide | 1 | 1991 | 640 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 1990 | 138 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 25903 | 0.010 |
Why?
|
| Salmonella enteritidis | 1 | 1989 | 17 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1993 | 437 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1995 | 2561 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 35447 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1990 | 1420 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1993 | 1603 | 0.000 |
Why?
|
| Dactinomycin | 1 | 1988 | 318 | 0.000 |
Why?
|
| Teratoma | 1 | 1990 | 395 | 0.000 |
Why?
|
| Up-Regulation | 1 | 1996 | 4194 | 0.000 |
Why?
|
| Bronchoscopy | 1 | 1993 | 867 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2010 | 41390 | 0.000 |
Why?
|
| Diagnosis, Differential | 2 | 1993 | 13042 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 2004 | 11553 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 3500 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 14761 | 0.000 |
Why?
|
| Lung | 1 | 1993 | 9990 | 0.000 |
Why?
|